Trial Profile
An Open-Label Randomized, Phase 2A, Dose-Ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Sotatercept (Primary)
- Indications Chemotherapy-induced anaemia
- Focus Therapeutic Use
- Sponsors Celgene Corporation; Merck Sharp & Dohme
- 24 Dec 2014 New trial record